Shots:
The P-III (BRUIN CLL-322) trial assessed Jaypirca + venetoclax & rituximab vs venetoclax & rituximab in r/r chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), with both arms treated ~2yrs. followed by therapy-free period until disease progression
The trial met its 1EP, demonstrating improved PFS per IRC, with consistent results across clinically relevant subgroups…
